(Q37807362)

23 August 2017

title

Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review (English)

1 reference

inflammatory bowel diseases

23 August 2017

main subject

0 references

inflammation

0 references

United States of America

1 reference

K T Park

1

1 reference

23 August 2017

Dorsey Bass

series ordinal

2

1 reference

23 August 2017

publication date

4 November 2010

1 reference

Inflammatory Bowel Diseases

23 August 2017

published in

1 reference

23 August 2017

volume

17

1 reference

23 August 2017

issue

7

1 reference

23 August 2017

page(s)

1603-1609

1 reference

Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences

23 August 2017

cites work

1 reference

The costs of Crohn's disease in the United States and other Western countries: a systematic review

21 January 2018

1 reference

The direct and indirect cost burden of Crohn's disease and ulcerative colitis

21 January 2018

1 reference

Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults

21 January 2018

1 reference

Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation.

21 January 2018

1 reference

Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital

21 January 2018

1 reference

Health care expenditures in ulcerative colitis: the perspective of a self-insured employer.

21 January 2018

1 reference

Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment.

21 January 2018

1 reference

Cost effectiveness of alternative imaging strategies for the diagnosis of small-bowel Crohn's disease

21 January 2018

1 reference

Diagnosing Crohn's disease: an economic analysis comparing wireless capsule endoscopy with traditional diagnostic procedures

21 January 2018

1 reference

Surveillance issues in inflammatory bowel disease: ulcerative colitis

21 January 2018

1 reference

Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates

21 January 2018

1 reference

Cost-effectiveness of quantitative fecal lactoferrin assay for diagnosis of symptomatic patients with ileal pouch-anal anastomosis.

21 January 2018

1 reference

A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis

21 January 2018

1 reference

The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis

21 January 2018

1 reference

A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine

21 January 2018

1 reference

Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines

21 January 2018

1 reference

Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting

21 January 2018

1 reference

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

Pharmacoeconomic considerations for inflammatory bowel disease in the era of biological therapies

21 January 2018

1 reference

Economics of the use of biologics in the treatment of inflammatory bowel disease

21 January 2018

1 reference

Management for severe Crohn's disease: a lifetime cost-utility analysis.

21 January 2018

1 reference

Resource use in patients with Crohn's disease treated with infliximab.

21 January 2018

1 reference

Cost-utility of initial medical management for Crohn's disease perianal fistulae.

21 January 2018

1 reference

A home infliximab infusion program

21 January 2018

1 reference

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

21 January 2018

1 reference

Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective.

21 January 2018

1 reference

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

21 January 2018

1 reference

Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease

21 January 2018

1 reference

Modified two-stage ileal pouch-anal anastomosis: equivalent outcomes with less resource utilization

21 January 2018

1 reference

Long-term direct costs before and after proctocolectomy for ulcerative colitis: a population-based study in Olmsted County, Minnesota.

21 January 2018

1 reference

Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares

21 January 2018

1 reference

Medication non-adherence is associated with increased medical health care costs

21 January 2018

1 reference

Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries.

21 January 2018

1 reference

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IBD.21488

1 reference

23 August 2017

1 reference